Physician

Mudussara Asad Khan, MD

According to 2025 Medicare claims, Mudussara Khan, MD (NPI: 1821290362) practices hematology/oncology in the Deltona-Daytona Beach-Ormond Beach, FL market, with the plurality of this provider's patient population coming from Volusia, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 32117-5122. Khan is affiliated with the Complete Health Accountable Care LLC (ACO ID: D0036), participating under the REACH model.

Khan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 596 traditional Medicare patients, billed 122,410 HCPCS/CPT codes, and received $1,828,290 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,436 prescription claims across 292 beneficiaries totaling $4,261,281 in drug costs, led by Revlimid (Lenalidomide). 2022 DME data shows 41 claims. Open Payments data shows 124 records totaling $2,515. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $633,450 to $1,828,290. Similarly, Part D prescription costs have risen steadily, from $164,911 to $4,261,281. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	268	38,687	$633,450
2016	333	39,952	$812,760
2017	368	45,980	$856,125
2018	362	74,669	$1,097,700
2019	441	101,590	$1,364,255
2020	367	95,258	$1,223,709
2021	599	127,078	$1,669,551
2022	710	136,640	$1,773,152
2023	507	146,159	$1,997,295
2024	596	122,410	$1,828,290

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	106	618	$164,911
2016	124	634	$287,419
2017	141	700	$646,038
2018	147	718	$1,081,432
2019	157	840	$1,884,934
2020	166	1,111	$2,774,563
2021	234	1,182	$2,105,539
2022	262	1,296	$2,472,651
2023	237	1,254	$2,930,461
2024	292	1,436	$4,261,281

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	39	$6,966
2019	N/R	72	$6,270
2020	N/R	33	$2,916
2021	N/R	11	$1,186
2022	N/R	41	$1,110
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	296	565	$94
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	291	486	$64
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	266	426	$13
36415	Insertion of needle into vein for collection of blood sample	400	1,038	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	416	1,280	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	65	1,820	$1,153,551
Xtandi	Enzalutamide	22	660	$303,400
Brukinsa	Zanubrutinib	22	660	$275,149
Imbruvica	Ibrutinib	17	476	$236,129
Ibrance	Palbociclib	12	336	$189,524

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	124	$2,515	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mudussara Asad Khan, MD?

Tedicare shows public-source Medicare data for Mudussara Asad Khan, MD (NPI 1821290362), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mudussara Asad Khan, MD have ACO affiliation data?

Mudussara Asad Khan, MD is shown with ACO affiliation data for Complete Health Accountable Care LLC (REACH, ACO ID D0036).

What billing organization is linked to Mudussara Asad Khan, MD?

Mudussara Asad Khan, MD is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Mudussara Asad Khan, MD have Open Payments data?

Mudussara Asad Khan, MD has 124 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.